TITLE

Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated �-Amyloid 1-42 Peptide

AUTHOR(S)
Dickey, Chad A.; Morgan, David G.; Kudchodkar, Sagar; Weiner, David B.; Bai, Yun; Cao, Chuanhai; Gordon, Marcia N.; Ugen, Kenneth E.
PUB. DATE
November 2001
SOURCE
DNA & Cell Biology;Nov2001, Vol. 20 Issue 11, p723
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by overproduction of �-amyloid (A�), which is formed from amyloid precursor protein (APP), with the subsequent pathologic deposition of A� in regions of the brain important for memory and cognition. Recently, vaccination of murine models of AD that exhibit A� deposition has halted or delayed the usual progression of the pathology of AD. Our group has demonstrated that vaccination of a doubly transgenic mouse model (expressing mutant APP and presenilin-1) with the A� 1-42 peptide protects these mice from the memory deficits they would ordinarily develop. This report further characterizes the A� 1-42 peptide vaccine in mice. Anti-A� response time course analysis indicated that at least three vaccinations (each 100 �g) were necessary to elicit a significant anti-A� titer. Subsequent vaccinations resulted in half-maximal antibody titers of at least 10,000, and these titers were maintained for at least 5 months after the final boost. Peptide binding competition studies indicated that the highest humoral responses are generated against the N terminus of the A� peptide. Also, measurement of specific murine Ig isotypes in A�-vaccinated mice demonstrated a predominant IgG[sub 1] and IgG[sub 2b] response, suggesting a type 2 (Th2) T-helper cell immune response, which drives humoral immunity. Finally, lymphocyte proliferation assay experiments using A� peptides and splenocytes from vaccinated mice demonstrated that the vaccine specifically stimulates T-cell epitopes present within the A� peptide.
ACCESSION #
5849363

 

Related Articles

  • Quantitative and Mechanistic Studies of Aβ Immunotherapy. Golde, Todd E.; Das, Pritam; Levites, Yona // CNS & Neurological Disorders - Drug Targets;2009, Vol. 8 Issue 1, p31 

    There is substantial and compelling evidence that aggregation and accumulation of amyloid β protein (Aβ) plays a pivotal role in the development of Alzheimer's disease (AD); thus, numerous strategies to prevent Aβ aggregation and accumulation or to facilitate removal of preexisting...

  • Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimer's Disease Immunotherapy. Ghochikyan, Anahit // CNS & Neurological Disorders - Drug Targets;2009, Vol. 8 Issue 2, p128 

    Amyloid-beta (A�) immunotherapy has received considerable attention as a promising approach for reducing the level of A� in the CNS of Alzheimer's disease patients. However, the first Phase II clinical trial, for the immune therapy AN1792, was halted when a subset of those immunized...

  • How to Get from Here to There: Macrophage Recruitment in Alzheimer's Disease. Rezai-Zadeh, K.; Gate, D.; Gowing, G.; Town, T. // Current Alzheimer Research;Mar2011, Vol. 8 Issue 2, p156 

    No abstract available.

  • Beta-Amyloid Peptides Enhance the Proliferative Response of Activated CD4+CD28+ Lymphocytes from Alzheimer Disease Patients and from Healthy Elderly. J�zwik, Agnieszka; Landowski, Jerzy; Bidzan, Leszek; F�lop, Tamas; Bryl, Ewa; Witkowski, Jacek M. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Alzheimer's disease (AD) is the most frequent form of dementia among elderly. Despite the vast amount of literature on non-specific immune mechanisms in AD there is still little information about the potential antigen-specific immune response in this pathology. It is known that early stages of...

  • Activation of innate immunity by lysozyme fibrils is critically dependent on cross-β sheet structure. Gustot, Adelin; Raussens, Vincent; Dehousse, Morgane; Dumoulin, Mireille; Bryant, Clare; Ruysschaert, Jean-Marie; Lonez, Caroline // Cellular & Molecular Life Sciences;Aug2013, Vol. 70 Issue 16, p2999 

    Inflammation occurs in many amyloidoses, but its underlying mechanisms remain enigmatic. Here we show that amyloid fibrils of human lysozyme, which are associated with severe systemic amyloidoses, induce the secretion of pro-inflammatory cytokines through activation of the NLRP3 (NLR, pyrin...

  • RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Donahue, John E.; Flaherty, Stephanie L.; Johanson, Conrad E.; Duncan,III, John A.; Silverberg, Gerald D.; Miller, Miles C.; Tavares, Rosemarie; Wentian Yang; Qian Wu; Sabo, Edmond; Hovanesian, Virginia; Stopa, Edward G. // Acta Neuropathologica;Oct2006, Vol. 112 Issue 4, p405 

    The receptor for advanced glycation end products (RAGE) is thought to be a primary transporter of β-amyloid across the blood–brain barrier (BBB) into the brain from the systemic circulation, while the low-density lipoprotein receptor-related protein (LRP)-1 mediates transport of...

  • The genetics of the amyloidoses: interactions with immunity and inflammation. Buxbaum, J. // Genes & Immunity;Sep2006, Vol. 7 Issue 6, p439 

    Historically, the amyloidoses have been associated with inflammation and the immune response. From Virchow's original description in human pathologic inflammatory states through their identification in horses used to produce antitoxin to their frequent occurrence in the course of multiple...

  • Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. Maezawa, Izumi; Maeda, Nobuyo; Montine, Thomas J.; Montine, Kathleen S. // Journal of Neuroinflammation;2006, Vol. 3, p10 

    Background: Inheritance of the three different alleles of the human apolipoprotein (apo) E gene (APOE) are associated with varying risk or clinical outcome from a variety of neurologic diseases. ApoE isoform-specific modulation of several pathogenic processes, in addition to amyloid β...

  • Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Aβ immunotherapy. Das, Pritam; Smithson, Lisa A.; Price, Robert W.; Holloway, Vallie M.; Levites, Yona; Chakrabarty, Paramita; Golde, Todd E. // Journal of Neuroinflammation;2006, Vol. 3, p17 

    Background: Microglial activation has been proposed to facilitate clearance of amyloid β protein (Aβ) from the brain following Aβ immunotherapy in amyloid precursor protein (APP) transgenic mice. Interleukin-1 receptor 1 knockout (IL-1 R1-/-) mice are reported to exhibit blunted...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics